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VHL down-regulation and differential localization as mecha-
nisms in tumorigenesis.
Background. The von Hippel-Lindau (VHL) gene has been
widely analyzed in many tumors. Early studies in animal tumors
suggest that changes in VHL protein level and localization may
be also important in tumorigenesis. In this study, we deter-
mined the role of VHL protein in human renal cell carcinomas.
Methods. Seventy-five human renal cell carcinomas, pre-
dominantly of clear cell type (60 of 75), were examined for
VHL protein by immunohistochemistry. The level and pattern
of protein expression were then compared to VHL mutations
and tumor characteristics.
Results. An apparent decline of VHL level (positive in
50% of tumor cells) was observed in 49 (65%) tumors, a
change more frequent than VHL mutations (28 of 75) (37%).
In tumors, VHL was localized to the cytoplasm and/or the cell
membrane. The occurrence of a predominantly membranous
signal was significantly associated with missense mutations (9
of 14 tumors with missense mutations versus 14 of 61 tumors
with no or nonmissense mutations, P  0.0025) and tumor
stage (23 of 60 tumors with stage TI versus 0 of 15 tumors with
TII and TIII, P  0.0034).
Conclusion. This study provides the first evidence of the
role of VHL protein level and intracellular localization in tu-
morigenesis in humans.
Germline loss of the chromosome 3p25 region, where
the von Hippel-Lindau (VHL) gene resides, and VHL
mutations, predispose affected family members to vari-
ous hypervascular tumors, including renal cell carcino-
mas [1]. This indicates that the VHL plays a fundamental
role in tumorigenesis and angiogenesis. Supporting evi-
dence from cellular analyses includes demonstrations of
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VHL as a tumor suppressor and as a regulator of angio-
genic factors, such as hypoxia-inducible factor 1-alpha
and vascular endothelial growth factor (VEGF) [2–4].
Loss of the chromosome 3p25 region has been also ob-
served in many sporadic tumors, with high frequency
in clear cell renal cell carcinoma (90%) [4, 5]. Gene
mutation in the VHL coding sequence is seen in about
30% to 60% of sporadic clear cell renal cell carcinoma
but is not commonly detected in other tumors [4–7],
suggesting that VHL mutation alone is not always suffi-
cient to account for contributions of VHL to tumor de-
velopment.
VHL protein is widely expressed in many normal and
neoplastic tissues [8–10]. Since VHL protein is also de-
tectable in clear cell renal cell carcinoma, mutation alter-
ing the protein structure has been believed to be the
major factor leading to inactivation of VHL tumor sup-
pression function. However, this assumption is chal-
lenged by a recent population-based study showing that
VHL mutation is associated with better survival in clear
cell renal cell carcinoma patients compared to those with
wild-type VHL allele [11]. Previously, we have reported
that VHL protein down-regulation is observed in rat non-
clear cell renal tumors [12], which are known to have no
detectable VHL intragenic mutations [13]. This prompted
us to examine whether the VHL protein expression is
altered in human renal cell carcinoma, with possible ge-




A total of 75 renal cell carcinomas were selected by
taking representative numbers of tumors with missense
mutations (14 cases), other types of mutations (14 cases),
and no detectable mutations (47 cases) from a popula-
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Fig. 1. Determination of von Hippel-Lindau (VHL) antibody specific-
ity using normal kidneys and cancer-positive controls (magnification,
200). Nonneoplastic areas of kidney: Ig32 antibody (A and C ); Ab-
1 antibody (B); IgG1 isotype antibody (D). Breast cancer: Ig32 antibody
(E); omission of Ig32 antibody (F).
tion-based database, in which VHL genotype has been
examined in 102 cases [14–16]. Histologic type (60 clear
cell tumors, 14 chromophilic tumors, and 1 chromophobe
tumor), nuclear grade, and tumor stage were determined,
as previously described [15, 17]. Formalin-fixed paraffin-
embedded serial sections of 5m were cut and submitted
for VHL immunohistochemistry.
Immunohistochemistry
A microwave antigen retrieval method, as described
previously [12], was used for immunohistochemical stain-
ing. In brief, dewaxed 5 m formalin-fixed paraffin-
embedded sections were immersed in a citrate buffer
(10 mmol/L sodium citrate, pH 6.0) and boiled in a micro-
wave oven at full power for 10 minutes. Endogenous
peroxidase activity was blocked with 0.3% H2O2 in meth-
anol for 30 minutes before addition of primary antibody.
A monoclonal antibody (Ig32) (BD Biosciences-Phar-
Mingen, San Diego, CA, USA), recognizing human VHL
amino acids 1-115 [18], was applied to samples at 1:200
dilution (2.5g/mL). Another antihuman VHL antibody
(Ab-1) (NeoMarkers, Fremont, CA, USA) against the
VHL 1-54 aa region at 1:100 dilution (2 g/mL) was also
used in some sections for validation. The avidin-biotin
Fig. 2. von Hippel-Lindau (VHL) brown immunosignal from Ig32 anti-
body in renal cell carcinomas. Cell membrane (A and B ) (magnification,
200); cytoplasm (C and D ) (magnification, 200); comparison of
signal between nonneoplastic [on the right (E ) and at the top-right
corner (F )] (magnification, 100) and corresponding tumor areas [on
the left (E) and at the bottom (F)].
complex procedure was used to detect presence of VHL
protein according to the manufacturer’s instruction (Vec-
tor Laboratory, Burlingame, CA, USA). Omission of the
primary antibody and use of an isotype control antibody
(IgG1) (BD Biosciences-PharMingen) at 5 g/mL, twice
the concentration of VHL antibodies used, were carried
out to test specificity of the immunostaining. Breast and/or
colon cancer positive control slides (Dako, Carpinteria,
CA, USA) were also included in each immunohisto-
chemical staining series. An imaging system, Olympus
Provis AX70 microscope (Lake Success, NY, USA) op-
erated by Zeiss AxioVision 3.0 software (Hallbergmoos,
Germany), was used to capture representative areas for
illustrations. The percentage of cells showing brown sig-
nal were semiquantitatively scored and categorized into
10%, 10% to 50%, and 50%. The immunostaining
was also classified into predominantly membranous or
cytoplasmic in location. The immunohistochemical stain-
ing was performed at least twice for each case and the
scoring was blinded to the sample identity.
Statistical analysis
Correlations of VHL immunosignal with VHL muta-
tion spectrum, tumor stage, and nuclear grade were ex-
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Table 1. Associations of von Hippel-Lindau (VHL) protein level and location with VHL genotype and tumor characteristics
VHL signal in tumor cells Location of VHL signal
Nonmembranec
Variables 10%a 10% to 50% 50% P valueb Membrane (cytoplasm; other) P valueb
VHL genotype 0.4237 0.0102
Missense 4 4 6 9 5 (1; 4)
Nonmissense 9 2 3 3 11 (3; 8)
No mutations 22 8 17 11 36 (12; 24)
Nuclear grade 0.1918 0.2214
1 3 2 7 6 6 (3; 3)
2 16 9 11 11 25 (7; 18)
3 and 4 16 3 8 6 21 (6; 15)
Tumor stage 0.3876 0.0034
TI 26 11 23 23 37 (10; 27)
TII and TIII 9 3 3 0 15 (6; 9)
a The majority of tumors (32/35) had no detectable immunosignal across entire tumor area
b Chi-square analysis, except the location of VHL signal versus tumor stage by Fisher exact test
c The numbers from cytoplasmic and “other” immunostaining were combined for statistical analysis. In the “other” category, 34 had VHL signal in 10% tumor
cells, including the 32 without detectable immunosignal.
amined by logistic regression contingency table using
the StatView software (Version 4.5, Abacus Concepts,
Berkeley, CA, USA). Probabilities were computed using
the likelihood ratio chi-square statistic or two-sided Fish-
er’s exact test as appropriate. The probability of less
than 0.05 was considered as of statistical significance.
RESULTS AND DISCUSSION
Validation of primary antibodies
Immunosignal was specifically detected in normal re-
nal tubules using either Ig32 or Ab-1 antibody, with
greater intensity in the proximal region, and no signal
was observed in glomeruli (Fig. 1 A to C). These observa-
tions are consistent with reports by others [8–10]. Mini-
mal or no background was observed when primary anti-
body was omitted or an IgG1 control antibody was
applied in the staining (Fig. 1D). Specificity of these
antibodies was further confirmed in other cancer controls
(Fig. 1E and F). Applicability of the Ig32 antibody in
formalin-fixed paraffin-embedded tissues is also demon-
strated here.
Differential localization of VHL protein
among tumors
In normal renal tubules, VHL immunostaining, ap-
pearing as a fine-granular signal, was observed primarily
in the cytoplasm, especially using the Ig32 antibody (Fig.
1 A and C). The Ab-1 antibody occasionally detected
accumulation of immunosignal on the cell membrane
(Fig. 1B). The granular signal in the cytoplasm has also
been seen in rat kidney and has been shown to be a
result of VHL localization to the mitochondria, in which
VHL alterations have implications for morphogenesis of
renal tumors [19, 20].
VHL immunosignal was rather diverse among the kid-
ney tumors. The brown signal was detected in the cyto-
plasm or on the cell membrane, as a rim-like signal (Fig.
2 A to D) (Table 1). In the “other” category of Table
1, two showed similar percentage of membranous and
cytoplasmic signal and the remaining 34 tumors had no
detectable immunostaining or signal too low for unam-
biguous localization. Membranous immunostaining has
been observed by others also [21, 22]. A consideration
was whether the apparent immunostaining on the cell
membrane could be due to peripheralization of cyto-
plasm by the occupancy of lipid and/or glycogen typical
of clear cells. However, it is evident that many cells
with membranous signal in Figure 2A and B also have
abundant cytoplasm with minimal cytoplasmic immuno-
staining, and that clear cells in Figure 2C and D lack the
rim-like immunosignal. These observations suggest that
the apparent membranous signal is not due to peripheral
cytoplasm. No signal was observed in nuclei of normal
and neoplastic cells.
Down-regulation of VHL protein in renal tumors
When the immuostaining was scored, 49 of 75 (65%)
tumors showed prominent VHL down-regulation (less
than 50% cells with positive immunosignal). Notably,
there were always some areas of no VHL immunosignal
in all 75 renal cell carcinomas. This alteration rate is
higher than mutation in the VHL gene (28 of 75) (37%),
suggesting that down-regulation of VHL protein is more
common than gene mutation. Heterogeneous popula-
tions were commonly seen in tumors and VHL immuno-
signal appeared to be often detected in areas containing
typical clear cell phenotype. A similar observation has
also been reported in other study [21]. In addition to
the semiquantitative scoring, down-regulation of VHL
protein level was further demonstrated by comparing
immunostaining intensity between tumors and adjacent
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nonneoplastic tissues (Fig. 2E and F). This direct com-
parison in samples with coexisting tumor and nonneo-
plastic tissues minimizes the contributions of slide-to
slide immunostaining variations.
Correlations of VHL phenotype with VHL genotype
and with tumor stage
The percentage of VHL-positive cells and location of
signal were subsequently compared with VHL mutation
spectra, nuclear grade, and tumor stage (Table 1). Tu-
mors carrying frameshift and nonsense (nonmissense)
mutations, resulting in truncated protein, tended to have
the lowest immunosignal scoring (10% positive cells,
9 of 14) compared to only 4 in 14 missense mutations
(P  0.058). This low percentage of immunosignal is
likely a result of poor antibody recognition to truncated
VHL proteins. Strikingly, membranous immunostaining
was significantly associated with missense mutations (Ta-
ble 1). The VHL genotypic and phenotypic concordance
was best demonstrated by combining tumors with non-
missense or no mutations. Missense mutations occurred
in 9 of 23 tumors with membranous signal versus in 5
of 52 tumors with other immunostaining patterns (P 
0.0025). Moreover, the membrane localization was sig-
nificantly associated with low tumor stage (Table 1).
None of 15 available tumors of stage TII and TIII showed
predominantly membranous immunostaining, compared
with 23 of 60 stage TI tumors (P  0.0034). Nuclear
grade was not associated with either percentage of VHL
signal or protein location.
The association of missense mutation and membra-
nous immunostaining has not been reported before. This
finding is provocative and suggests that mutated VHL
proteins with amino acid substitutions may have clinical
implications, as evidenced by the association between
membranous immunosignal and low tumor stage. This
prediction of tumor progression by location of VHL sig-
nal is potentially important and requires validation from
more population-based studies.
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